Cytodyn INC

CytoDyn announced promising early clinical results for leronlimab in metastatic colorectal cancer and outlined its 2026 development strategy.

CytoDyn Inc. announced the extension of two secured convertible promissory notes totaling $57 million by 36 months, coupled with a reduced annual interest rate and monthly stock payments.

CytoDyn Inc. announced multiple unregistered sales of equity securities and warrants, raising approximately $18.8 million in cash and converting $1.5 million in debt to equity.

CytoDyn Inc. has reached an agreement in principle to settle a securities class action lawsuit for $500,000 in cash and 49 million shares of common stock.

CytoDyn Inc. stockholders approved an increase in authorized common stock and re-elected its board of directors at the 2025 Annual Meeting.

CytoDyn Inc. has secured a $30 million standby equity purchase agreement with Yorkville Advisors Global, providing flexible capital for working capital and general corporate purposes.

CytoDyn Inc. files its Q3 2026 Form 10-Q, detailing financial performance, operational updates, and ongoing legal matters.

CytoDyn Inc. reported a significant net loss for Q2 2026, settled a major class-action lawsuit, and disclosed substantial doubt about its ability to continue as a going concern.

CytoDyn Inc. reported a net loss of $5.54 million for the quarter ended August 31, 2025, and disclosed substantial doubt about its ability to continue as a going concern.

CytoDyn Inc. reports a net income of $9.7 million for the nine months ended February 28, 2025, primarily due to a legal settlement, while facing ongoing legal proceedings and financial uncertainties.

CytoDyn Inc. reports a net income of $14.5 million for the six months ended November 30, 2024, primarily due to a settlement with Amarex, while highlighting ongoing efforts in clinical development of leronlimab.

CytoDyn reports a net income of $19.2 million for the quarter ended August 31, 2024, primarily due to a settlement with Amarex, while also highlighting ongoing financial challenges and the need for additional funding.

CytoDyn Inc. announced a net income of $3.7 million for fiscal year 2025, primarily due to a $25.0 million legal settlement, as it refocuses its clinical development on solid-tumor oncology while facing significant liquidity challenges and ongoing regulatory investigations.

CytoDyn Inc. has filed an amendment to its annual report to include previously omitted information and correct an exhibit, with no changes to previously reported financial results.

CytoDyn Inc.'s annual 10-K filing details a strategic pivot towards oncology and inflammation research, alongside the development of a long-acting version of their drug, leronlimab.

CytoDyn Inc. director Tanya Durkee Urbach received a grant of 574,385 non-qualified stock options with an exercise price of $0.28, vesting monthly through March 2027.

CytoDyn Inc. Director Stephen M. Simes was granted 574,385 non-qualified stock options at an exercise price of $0.28, vesting monthly over one year.

CytoDyn Inc. Director Lishomwa C Ndhlovu received an annual grant of 574,385 non-qualified stock options with an exercise price of $0.28, vesting monthly over one year.

CytoDyn Inc.'s CEO, Jacob P. Lalezari, was granted 4,874,691 non-qualified stock options with an exercise price of $0.28, vesting over several years.

CytoDyn Inc.'s Chief Financial Officer, Robert E. Hoffman, was granted 4,874,691 non-qualified stock options with an exercise price of $0.28.

CytoDyn Inc. director Ryan Dunlap was granted 574,385 non-qualified stock options with an exercise price of $0.28, vesting monthly over one year.

CytoDyn Inc. announced a $30 million standby equity purchase agreement with Yorkville Advisors Global to provide flexible capital for working capital and general corporate purposes.

CytoDyn Inc. reports significant progress in its leronlimab oncology program, particularly in mTNBC and mCRC, alongside the closure of SEC and DOJ investigations.

CytoDyn Inc. announces its 2025 Annual Meeting of Stockholders to vote on director elections, auditor ratification, executive compensation, and a significant increase in authorized common stock.

CytoDyn Inc. will hold its 2024 Annual Meeting of Stockholders virtually on November 22, 2024, to vote on the election of directors, ratification of auditors, and executive compensation.

CytoDyn Inc. has filed a registration statement for the resale of up to 278 million shares of common stock and shares underlying warrants.

CytoDyn Inc. is registering for resale up to 486.6 million shares of its common stock by selling stockholders, as the company continues clinical development of leronlimab for various indications.

CytoDyn Inc. has filed an S-1 registration statement with the SEC to allow selling stockholders to resell up to 141,019,099 shares of common stock, including shares underlying warrants.